Authors: Giacomo Pongiglione Alessandro Possidoni Umberto di Luzio Paparatti Anna Maria Costanzo Giuliana Gualberti Marco Bonvicini Alessandro Rimini Gabriella Agnoletti Maria Pia Calabrò Marco Pozzi Roberto Tumbarello Patrizia Salice Patrizio Fiorini Maria Giovanna Russo Ornella Milanesi
Publish Date: 2016/08/29
Volume: 37, Issue: 8, Pages: 1581-1589
Abstract
Children affected by hemodynamically significant congenital heart disease HSCHD experience severe respiratory complications that can increase the frequency of hospitalizations The aim of the SINERGY study was to describe the incidence of respiratory diseases and to collect information on active and passive immunoprophylaxis in the first 2 years of life In this retrospective multicenter and epidemiologic study children with HSCHD were enrolled across 11 Italian sites Children born between December 31 2007 and December 31 2012 were observed during their first 2 years of life Data were collected through hospital database searches and parent interviews Four hundred twenty children were enrolled 517 were female 795 were born fullterm ≥37 weeks and 776 weighed 2500 g at birth The most frequent heart defects were ventricular septal defect 231 and coarctation of the aorta 143 The incidence of respiratory diseases was 631 Frequent respiratory diseases not requiring hospitalization were upper respiratory tract infections 764 acute bronchitis 433 and influenza 221 while those requiring hospitalization were bronchitis and bronchiolitis 83 each one While active immunoprophylaxis was applied with wide compliance diphtheria/pertussis/tetanus 995 Haemophilus influenzae type b 725 pneumococcus 799 meningococcus 774 only 54 of children received respiratory syncytial virus RSV passive prophylaxis palivizumab Of the 35 hospitalizations due to bronchiolitis 27 771 did not receive prophylaxis against RSV compared with 8 229 who received prophylaxis P 00001 Children with HSCHD are at major risk of respiratory diseases Passive immunoprophylaxis can help to prevent hospitalizations for bronchiolitisAbbVie and the steering committee appreciate all the people who gave their support in the conduct of this study Anna Ingargiola Giulio Calcagni Francesco De Luca Concetta Ricci Marianna Fabi Lucia Manuri Sabrina Montis Monica Pelegrini Eliana Franchi Daniela Poli Emanuela Portas Carmen Privitera Colin Gerard Egan Lisa Serafini and Lucia Trevisan An abstract from the SINERGY study was published in Cardiology in the Young A poster was presented at the 49th Annual Meeting of the Association for European Paediatric and Congenital Cardiology May 20–23 2015 Prague Czech RepublicULP and AMC participated in the design of the study and interpretation of data AP and GG participated in interpretation of data and writing of the manuscript GP MB AR GA MPC MP RT PS PF MGR and OM were involved in the acquisition of data from the different clinical centers All authors were involved in drafting the manuscript and read and approved the final manuscriptAbbVie was responsible for the design conduct analysis and funding of the study AbbVie participated in the interpretation of data writing review and approval of this publication Umberto di Luzio Paparatti Anna Maria Costanzo and Giuliana Gualberti are employees of AbbVie and may own AbbVie stock options Alessandro Possidoni was an employee of AbbVie Giacomo Pongiglione and Ornella Milanesi are consultants for Abbvie Marco Bonvicini Maria Pia Calabrò Alessandro Rimini Patrizia Salice Maria Giovanna Russo Marco Pozzi Roberto Tumbarello Patrizio Fiorini and Gabriella Agnoletti declared no conflict of interest
Keywords: